Tyra Biosciences Announces First Child Dosed in BEACH301 Phase 2 Clinical Study for Achondroplasia Treatment

Tyra Biosciences has filed a Form 8-K with the U.S. Securities and Exchange Commission, announcing that the first child has been dosed in the BEACH301 Phase 2 clinical study of dabogratinib (formerly TYRA-300) in children with achondroplasia. The Company expects to report initial results from the safety sentinel cohort of the BEACH301 study in the second half of 2026.

Key Takeaways:

• Tyra Biosciences has initiated the BEACH301 Phase 2 clinical study of dabogratinib for the treatment of achondroplasia in children, with the first participant dosed on August 21, 2025.
• The study aims to evaluate the safety and efficacy of dabogratinib in this patient population, with initial results expected in the second half of 2026.
• The Company has submitted its report to the U.S. Securities and Exchange Commission through a Form 8-K filing, outlining the study's progress and potential risks.
• Forward-looking statements have been made regarding the study's expected outcomes, including the reporting of initial results and potential delays in clinical trials.
• The Company has highlighted several risks associated with the study, including potential delays, adverse side effects, and regulatory developments.

Statistics:

• August 21, 2025: Date of the first child dosed in the BEACH301 Phase 2 clinical study.
• 2026: Expected year of reporting initial results from the safety sentinel cohort of the BEACH301 study.
• 2656 State Street, Carlsbad, California 92008: Address of Tyra Biosciences' Principal Executive Offices.
• (619) 728-4760: Phone number of Tyra Biosciences with area code.

Sources:

• UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT (filed on August 22, 2025)
• Tyra Biosciences, Inc.'s annual report on Form 10-K (Prior filings with the SEC, including under the heading "Risk Factors")